Carl Zeiss Meditec AG (CHIX:AFXd)

Q3 2025 Carl Zeiss Meditec AG Earnings Call Transcript

Aug 7, 2025 / 05:00 AM GMT

Release Date Price: €43.37 (-9.48%)

Transcript

Key Points

Positve

Carl Zeiss Meditec AG (CZMWF) reported a strong order entry, with orders reaching 1.7 billion, marking a 23% increase.
Revenue reached 1.6 billion, an increase of 8% compared to the prior year, with recurring revenue at an all-time high, accounting for 51% of total revenue.
The VisMax 800 rollout in China has been successful, with over 50 devices installed by the end of June and a total order book of over 100 units.
EBTA margin improved to 11.1%, up from the previous year's 10.2%, driven by growth in the refractive market and strict cost control.
The company has a strong market and innovation leadership in China and globally, with significant growth opportunities outside of China, particularly in markets like Japan and India.

Negative

The EBTA margin was at 11%, moderately below last year's 11.4%, due to pressures in the equipment business segment.
US tariffs had a mid-single-digit EUR bottom line impact, and the full impact of new pricing adjustments will only begin to materialize in the next fiscal year.
The neurosurgery business continues to remain soft, largely due to the ongoing product cycle transition to the Geneva 900.
Net income declined from €108 million to €89 million, and earnings per share dropped by 24% compared to last year.
The company faces challenges from geopolitical conflicts, trade wars, increasing regulation, and competition from low-cost players, particularly in China.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AFXG.DE - Carl Zeiss Meditec AG
Q3 2025 Carl Zeiss Meditec AG Earnings Call
Aug 07, 2025 / 05:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Carlize Medich AT analyst Conference regarding the 9 months 2024-25 results. At this time, all participants have been placed on the listen-only mode. The floor will be open for your questions following the presentation. Let me now turn the floor over to Sebastian Frerichs, head of investor relations.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to our 9 month 24, 25 analyst conference call. I'm Sebastian. I'm the head of investor relations of Calde Medich, and with me today are our CEO Maximilian

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.